Testing Olanzapine or Dexamethasone to Prevent Delayed Nausea After Stem Cell Transplant in Myeloma
Compares two anti-nausea drug combinations in adults with multiple myeloma having a stem cell transplant.
Plain-language title generated from the registry record
Registry title: Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Key facts
- Where
- Ningbo, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07413809, who can take part
Where in China
- The Affiliated People's Hospital of Ningbo UniversityNingbo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated People's Hospital of Ningbo University
- Trial code
- NCT07413809
- Record updated
- 17 February 2026
- Original description
This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced by high-dose chemotherapy during HSCT.Read full original descriptionShow less
A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced by high-dose chemotherapy during HSCT.
Inclusion: Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation; Preconditioning regimen consists of melphalan at a dose of 200 mg/m²; ECOG performance status score of 0 to 2; Age >18 years and <65 years; Expected survival time >3 months; Absence of intracranial hypertension, gastrointestinal obstruction, or other causes of refractory vomiting; Ability to understand and provide written informed consent.
Exclusion: Presence of nausea or vomiting within 48 hours prior to enrollment, with prior use of antiemetic medications; Current use or use within the past month of CYP3A4 inducers, inhibitors, or substrate drugs; History of hypersensitivity to fosaprepitant or olanzapine; Serum creatinine clearance <60 mL/min; Inability to receive treatment and follow-up at the designated study site, or inability to comprehend, comply with the study protocol, or provide informed consent.